文献速递其他结缔组织病

B细胞治疗干燥综合征的外周血转录组重塑与ESSDAI及STAR应答基线预测因子

Treatment-Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of ESSDAI and STAR Response to B Cell Therapy in Sjögren's Disease.
PubMed 文献 · Arthritis Rheumatol · 2026-09-24

本研究对43例活动性干燥综合征患者(来自2期GSK试验NCT02631538)在基线及第24周进行全血RNA测序,比较利妥昔单抗、贝利尤单抗、序贯BEL-RTX与安慰剂。序贯BEL-RTX诱导最大转录组变化;ESSDAI无应答与基线TGFβ-2、C4A、CD8A高表达及C4BPA低表达相关(AUC 0.89),STAR无应答与IL-1/IL-18/FcγR髓系模块高表达相关(AUC 0.80),两套标志物完全不重叠。

要点

  • 序贯BEL-RTX在24周诱导最大转录组改变。
  • ESSDAI无应答基线标志物AUC 0.89,涉及补体与TGFβ-2通路。
  • STAR无应答基线标志物AUC 0.80,涉及IL-1/IL-18/FcγR模块。

核心结论

  • ESSDAI与STAR的配体-受体标志物完全不同,提示B细胞治疗无应答由不同系统性生物驱动因素所致。
  • 两套标志物完全不重叠,提示存在不依赖B细胞的顽固炎症回路。

研究设计与样本

  • 对2期GSK试验(NCT02631538)中43例活动性干燥综合征成人患者,在基线及第24周行全血RNA测序。
  • 比较利妥昔单抗、贝利尤单抗、序贯BEL-RTX与安慰剂,差异表达分析条件为倍数变化>1.5且未校正P<0.01。
  • 整合通路富集与配体-受体分析,应答定义采用ESSDAI和STAR。

主要发现

  • 序贯BEL-RTX从基线至第24周诱导最大的转录组变化。
  • ESSDAI无应答与基线TGFβ-2、C4A、CD8A表达较高及C4BPA表达较低相关,涉及补体调节、细胞毒及基质重塑通路(AUC 0.89)。
  • STAR无应答者基线SPP1、TLR4、IL1R1、IL18R1、IL1RAP、TREM1及FCGR2A表达较高,形成以IL-1/IL-18/FcγR为中心的髓系模块(AUC 0.80)。
  • ESSDAI与STAR的配体-受体基因无重叠;ESSDAI基因可明显区分无应答者,STAR基因区分较弱且两定义间无聚类一致性。

关键数值与推荐

  • 临床应答采用EULAR干燥综合征疾病活动指数(ESSDAI)和干燥综合征应答评估工具(STAR)定义。
  • 差异表达阈值:倍数变化>1.5,未校正P<0.01。
  • ESSDAI无应答预测模型AUC 0.89;STAR无应答预测模型AUC 0.80。

临床怎么用

  • 基线外周血转录组标志物可能协助预判B细胞治疗无应答风险。
  • 补体调节、TGFβ-2介导重塑、IL-1/IL-18信号及FcγR激活可作为B细胞靶向治疗之外的候选通路。

局限性

  • 样本量43例,来自单一行2期试验,结果需更大队列验证。
  • 差异表达采用未校正P<0.01,未报告多重校正。
  • STAR相关基因对无应答者的区分较弱且与ESSDAI无聚类一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to characterize whole blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti-CD20 or B lymphocyte stimulator/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to nonresponse. METHODS: Whole blood RNA sequencing was performed at baseline and Week 24 in participants (n = 43) from a phase 2 GSK trial (NCT02631538) evaluating rituximab (RTX), belimumab (BEL), and sequential BEL-RTX versus placebo. Differential expression (DESeq2; fold change >1.5; unadjusted P < 0.01) was integrated with pathway enrichment and ligand-receptor analyses (Metascape, gene set enrichment analysis, curated interaction databases). Clinical response was defined using EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) and Sjögren's Tool for Assessing Response (STAR); responder groups were compared using descriptive statistics, correlations, and logistic regression with receiver operating characteristic-based evaluation. RESULTS: Sequential BEL-RTX induced the largest transcriptional shift from baseline to Week 24. Baseline differential expression identified distinct ligand-receptor predictors for each response definition. ESSDAI nonresponse was associated with higher baseline transforming growth factor β-2 (TGFβ-2), C4A, and CD8A expression, and lower complement component 4 BP alpha (C4BPA) expression, defining complement-regulated, cytotoxic, and stromal-remodeling pathways (area under the curve [AUC] 0.89). In contrast, STAR nonresponders showed higher baseline expression of SPP1, TLR4, IL1R1, IL18R1, IL1RAP, TREM1, and FCGR2A, forming an IL-1/IL-18/FcγR-centered myeloid module (AUC 0.80). No ligand-receptor genes overlapped between ESSDAI and STAR. ESSDAI genes clustered nonresponders distinctly, whereas STAR genes showed weak separation with no cluster concordance between the two response definitions. CONCLUSION: The distinct ESSDAI and STAR ligand-receptor signatures indicate different systemic biologic drivers of nonresponse to B cell therapies in SjD. Their complete nonoverlap suggests entrenched B cell-independent inflammatory circuits, highlighting complement regulation, TGFβ-2-mediated remodeling, IL-1/IL-18 signaling, and FcγR activation as rational treatment pathways beyond B cell-targeted therapies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ibrahim A, Peng J, Tian E, et al. Treatment-Driven Peripheral Blood Transcriptomic Remodeling and Baseline Predictors of ESSDAI and STAR Response to B Cell Therapy in Sjögren's Disease. Arthritis Rheumatol. 2026. PMID: 42781881. doi:10.1002/art.70354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。